APBB1IP (amyloid beta precursor protein binding family B member 1 interacting protein) functions as a critical adaptor molecule in integrin activation and cell adhesion signaling. The protein mediates Rap1-induced adhesion by facilitating the recruitment and membrane tethering of talin to activate integrin receptors 1. Specifically, APBB1IP (also known as RIAM) acts as a Rap1 effector that forms an 'integrin activation complex' at the plasma membrane, leading to unmasking of the integrin-binding site on talin and subsequent integrin activation 1. While talin's interaction with RIAM was found to be dispensable for integrin activation, Rap1 binding to talin's F0 and F1 domains synergizes with membrane lipid interactions to regulate integrin activity 2. Beyond integrin signaling, APBB1IP demonstrates broader disease relevance. The gene is associated with schizophrenia susceptibility and prepulse inhibition deficits in both mice and humans 3, with coexpression patterns linking it to immune system genes 3. In melanoma brain metastases, elevated APBB1IP levels correlate with increased tumor-associated macrophage infiltration and immune activation 4. Additionally, circular RNA derived from APBB1IP (circ-APBB1IP) is upregulated in clear cell renal cell carcinoma and promotes cancer progression through ERK1/2 signaling 5. APBB1IP expression is also associated with coronary artery involvement in Kawasaki disease 6, suggesting roles in both inflammatory and oncogenic processes.